

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Town Health International Medical Group Limited
康健國際醫療集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 3886)

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING
AND
(2) APPOINTMENT OF EXECUTIVE DIRECTORS AND
INDEPENDENT NON-EXECUTIVE DIRECTOR**

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that all the resolutions as set out in the AGM Notice were duly passed at the AGM held on 28 June 2022.

**APPOINTMENT OF EXECUTIVE DIRECTORS AND INDEPENDENT
NON-EXECUTIVE DIRECTOR**

The Board also announces that, with effect from the conclusion of the AGM, (i) each of Mr. Ng Ting Chi, Dr. Wong Chi Kit Nelson, Dr. Law Kwan Kin, Ms. Yao Yuan, Ms. Lau Wai Yee, Susanna and Dr. Wong Chun Wa has been appointed as an executive Director; and (ii) Mr. Chui Tsan Kit has been appointed as an independent non-executive Director.

Following the appointment of the above additional executive Directors, the number of the independent non-executive Directors falls below one-third of the Board as required under Rule 3.10(A) of the Listing Rules. The Company will identify suitable candidate to fill the vacancy within three months. Further announcement will be made by the Company when the relevant appointment is made.

Reference is made to the circular of Town Health International Medical Group Limited (“**Company**”) dated 2 June 2022 and the supplemental circular of the Company dated 14 June 2022 (collectively, the “**Circular**”) in relation to the proposals for re-election of retiring directors, general mandates to issue shares and to repurchase shares, declaration of final dividend, amendments to the bye-laws and appointment of the nominated Directors. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that all the resolutions as set out in the notice convening the AGM dated 2 June 2022 and the supplemental notice convening the AGM dated 14 June 2022 (collectively, the “**AGM Notice**”) were duly passed by the Shareholders by way of poll at the AGM held on 28 June 2022.

As at the date of the AGM, there were a total of 7,526,134,452 Shares in issue. No Shareholder has stated in the Circular that he/she/it intended to vote against or would abstain from voting in respect of any resolutions proposed at the AGM. To the best of the Directors’ knowledge, information and belief after having made all reasonable enquiries, there was no Share entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the AGM and no Shareholder was required to abstain from voting on any of the resolutions proposed at the AGM. As such, there were a total of 7,526,134,452 Shares, representing 100% of the issued share capital of the Company as at the date of the AGM, entitling Shareholders to attend and vote for or against the resolutions proposed at the AGM.

Full text of the resolutions is set out in the AGM Notice. The poll results for those resolutions are as follows:

Ordinary resolutions		Number of Shares (Approximate %)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company, the report of the Directors and the independent auditor’s report for the year ended 31 December 2021.	5,598,913,308 (100.0000%)	0 (0.0000%)

Ordinary resolutions		Number of Shares (Approximate %)	
		For	Against
2.	To declare a final dividend of HK0.15 cent per ordinary share for the year ended 31 December 2021.	5,598,913,308 (100.0000%)	0 (0.0000%)
3.	To re-elect the following retiring Directors:		
	(a) Mr. Hou Jun as a non-executive Director;	4,153,322,279 (74.1809%)	1,445,591,029 (25.8191%)
	(b) Mr. Ho Kwok Wah, George, <i>MH</i> as an independent non-executive Director; and	5,592,640,308 (99.8880%)	6,273,000 (0.1120%)
	(c) Mr. Yu Xuezhong as an independent non-executive Director.	4,168,574,544 (74.4533%)	1,430,338,764 (25.5467%)
4.	To authorise the Board to fix the directors' remuneration.	5,598,913,308 (100.0000%)	0 (0.0000%)
5.	To re-appoint Moore Stephens CPA Limited as the auditors of the Company and authorise the Board to fix their remuneration.	5,598,913,308 (100.0000%)	0 (0.0000%)
6.	To grant a general mandate to the Directors to allot, issue or otherwise deal with new Shares not exceeding 20% of the number of issued Shares as described in resolution no. 6 of the AGM Notice.	5,578,034,043 (99.6271%)	20,879,265 (0.3729%)
7.	To grant a general mandate to the Directors to repurchase Shares not exceeding 10% of the number of issued Shares as described in resolution no. 7 of the AGM Notice.	5,598,913,308 (100.0000%)	0 (0.0000%)
8.	To add the number of Shares repurchased to the number of Shares that may be issued pursuant to the general mandate granted to the Directors under resolution no. 6 above as described in resolution no. 8 of the AGM Notice.	5,578,034,043 (99.6271%)	20,879,265 (0.3729%)

Ordinary resolutions		Number of Shares (Approximate %)	
		For	Against
9.	To appoint Mr. Ng Ting Chi as a Director.	3,796,960,399 (67.8160%)	1,801,952,909 (32.1840%)
9A.	To appoint Dr. Wong Chi Kit Nelson as a Director.	3,792,513,399 (67.7366%)	1,806,399,909 (32.2634%)
9B.	To appoint Dr. Law Kwan Kin as a Director.	3,792,513,399 (67.7366%)	1,806,399,909 (32.2634%)
9C.	To appoint Ms. Yao Yuan as a Director.	3,792,513,399 (67.7366%)	1,806,399,909 (32.2634%)
9D.	To appoint Mr. Chui Tsan Kit as a Director.	3,792,513,399 (67.7366%)	1,806,399,909 (32.2634%)
9E.	To appoint Ms. Lau Wai Yee, Susanna as a Director.	3,792,513,399 (67.7366%)	1,806,399,909 (32.2634%)
9F.	To appoint Dr. Wong Chun Wa as a Director.	3,792,513,399 (67.7366%)	1,806,399,909 (32.2634%)
Special resolution			
10.	To approve the adoption of the amended and restated bye-laws of the Company.	5,578,034,043 (99.6271%)	20,879,265 (0.3729%)

Note: The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the AGM in person, by authorised corporate representative or by proxy.

As more than 50% of the votes were cast in favour of each of the above ordinary resolutions, the above ordinary resolutions were duly passed by the Shareholders as ordinary resolutions of the Company.

As more than 75% of the votes were cast in favour of resolution number 10 above, resolution number 10 above was duly passed by the Shareholders as a special resolution of the Company.

Tricor Tengis Limited, the branch share registrar and transfer office of the Company in Hong Kong, was appointed as the scrutineer for the vote-taking at the AGM.

All the Directors attended the AGM.

APPOINTMENT OF EXECUTIVE DIRECTORS AND INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that, with effect from the conclusion of the AGM, (i) each of Mr. Ng Ting Chi, Dr. Wong Chi Kit Nelson, Dr. Law Kwan Kin, Ms. Yao Yuan, Ms. Lau Wai Yee, Susanna and Dr. Wong Chun Wa has been appointed as an executive Director; and (ii) Mr. Chui Tsan Kit has been appointed as an independent non-executive Director.

The biographical details of Mr. Ng, Dr. CK Wong, Dr. Law, Ms. Yao, Mr. Chui, Ms. Lau and Dr. CW Wong are set out below:

(a) Mr. Ng

Mr. Ng Ting Chi, aged 34, was appointed as an executive Director on 28 June 2022.

Mr. Ng is a qualified member of Hong Kong Institute of Certified Public Accountants and CPA Australia. Mr. Ng obtained a degree of Bachelor of Economics in Financial Economics and Finance from University of New South Wales in 2009. Mr. Ng has over 12 years of experience in accounting, investment, corporate financial management and financial services. Prior to joining the Company, Mr. Ng has worked in one of the big four audit firms, two investment banks and served as General Manager in Power Financial Group Limited (a company listed on the main board of the Stock Exchange under stock code: 397).

Mr. Ng has entered into a letter of appointment with the Company as an executive Director for a term commenced on 28 June 2022 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment entered into between the Company and Mr. Ng, Mr. Ng is entitled to an emolument of HK\$20,000 per month which was determined by the Board with reference to his duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Ng does not (i) hold any other position with the Company or other members of the Group; (ii) hold any other major appointment and professional qualification; and (iii) have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meanings ascribed to them in the Listing Rules) of the Company.

As at the date of this announcement, Mr. Ng (i) did not hold any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (ii) does not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Ng as an executive Director that need to be brought to the attention of the Shareholders.

(b) Dr. CK Wong

Dr. Wong Chi Kit Nelson, aged 68, was appointed as an executive Director on 28 June 2022. Dr. CK Wong is the chief executive of Dr. Vio & Partners Limited, a non-wholly owned subsidiary of the Company.

Dr. CK Wong received his medical education at the University of London on a British Council Scholarship. In 1981, he passed his Diploma of Membership of the Royal Colleges of Physicians of the United Kingdom, MRCP (UK). He subsequently embarked on a self-study course in insurance operations and was awarded the Fellowship Diploma of the Life Management Institute (FLMI) with Distinction in 1987. He was formerly a part-time Consultant of several major insurers.

He is a serial entrepreneur, having built and sold 3 successful medical firms to listed companies. In 1982, he co-founded Allied Medical Practices Guild with an innovative structure and a disruptive business model. He pioneered a unique intranet Point-of-Sale system to facilitate front-line eligibility checking and back-office Electronic Data Interchange in 1998, before e-commerce became fashionable. He tried to retire in 2003, only to be lured out of retirement in 2005 to take the helm at Dr. Vio & Partners Limited.

He was the invited author of a book chapter on Managed Care in The University of Hong Kong position book on Hong Kong's Health System in 2006. He served on the Working Group on Primary Care under the HKSAR Government's Health and Medical Development Advisory Committee from 2008–2016. He is a Vice-Chairman of the Business and Professionals Federation of Hong Kong. His latest innovation is effective Pharmacy Benefit Management.

Dr. CK Wong was a director of Ringbell Company Limited (“**Ringbell**”), a private company incorporated in Hong Kong and dissolved by deregistration on 15 August 2003 under section 291AA of the then prevailing Companies Ordinance (Chapter 32 of the Laws of Hong Kong). Ringbell was inactive before deregistration. As confirmed by Dr. CK Wong, Ringbell was solvent prior to its dissolution.

Dr. CK Wong has entered into a letter of appointment with the Company as an executive Director for a term commenced on 28 June 2022 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment entered into between the Company and Dr. CK Wong, Dr. CK Wong is entitled to an emolument of HK\$20,000 per month which was determined by the Board with reference to his duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions. Pursuant to the employment contract entered into between Dr. CK Wong and Dr. Vio & Partners Limited, Dr. CK Wong is entitled to remuneration of HK\$419,605 per month, which was determined with reference to his duties and responsibilities with Dr. Vio & Partners Limited and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Dr. CK Wong does not (i) hold any other position with the Company or other members of the Group; and (ii) hold any other major appointment and professional qualification.

As at the date of this announcement, Dr. CK Wong (i) did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not have any interests in the Shares within the meaning of Part XV of the SFO; and (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meanings ascribed to them in the Listing Rules) of the Company.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Dr. CK Wong as an executive Director that need to be brought to the attention of the Shareholders.

(c) Dr. Law

Dr. Law Kwan Kin, aged 52, was appointed as an executive Director on 28 June 2022. Dr. Law is a director of Easy Result Limited, a subsidiary of the Company. Dr. Law is a registered medical practitioner in Hong Kong.

Dr. Law obtained Degrees of Bachelor of Medicine and Bachelor of Surgery from the Chinese University of Hong Kong in December 1994. Dr. Law was elected to the Membership of the Royal Colleges of Physicians of the United Kingdom in April 1997, as a Fellow by Hong Kong College of Physicians in October 2001, as a Fellow of the Hong Kong Academy of Medicine in the specialty of Medicine in May 2002 and as a Physician Fellow of the Royal College of Physicians and Surgeons of Glasgow in November 2007. Dr. Law has been accredited in Internal Medicine from July 2001 and in Cardiology from January 2004 by Hong Kong College of Physicians.

Dr. Law worked in the Department of Medicine and Geriatrics, Tuen Mun Hospital as Medical Officer from 1995 to 2006. Mr. Law has worked as a Medical Director with Hong Kong Cardiac Centre since 2006 and Hong Kong Cardiac Diagnostic Centre since 2017.

Dr. Law has entered into a letter of appointment with the Company as an executive Director for a term commenced on 28 June 2022 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment entered into between the Company and Dr. Law, Dr. Law is entitled to an emolument of HK\$20,000 per month which was determined by the Board with reference to his duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

As at the date of this announcement, Dr. Law has interests in 4,000 Shares within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, Dr. Law does not (i) hold any other position with the Company or other members of the Group; (ii) hold any other major appointment and professional qualification; and (iii) have any interests in the Shares within the meaning of Part XV of the SFO.

As at the date of this announcement, Dr. Law (i) did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (ii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meanings ascribed to them in the Listing Rules) of the Company.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Dr. Law as an executive Director that need to be brought to the attention of the Shareholders.

(d) Ms. Yao

Ms. Yao Yuan, aged 38, was appointed as an executive Director on 28 June 2022.

Ms. Yao obtained a degree of Bachelor of Science in Business Administration from Troy University in May 2006, and a degree of Master of Corporate Governance from Hong Kong Metropolitan University in November 2021.

Ms. Yao has more than 16 years of experience in management, business development and investor relations. Ms. Yao worked with the Group from September 2010 to September 2021 with her last position as IR & Coordination Director.

Ms. Yao has entered into a letter of appointment with the Company as an executive Director for a term commenced on 28 June 2022 to 31 December 2024, and she will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment entered into between the Company and Ms. Yao, Ms. Yao is entitled to an emolument of HK\$20,000 per month which was determined by the Board with reference to her duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

As at the date of this announcement, Ms. Yao has interests in 120,000 Shares within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, Ms. Yao does not (i) hold any other position with the Company or other members of the Group; (ii) hold any other major appointment and professional qualification; and (iii) have any interests in the Shares within the meaning of Part XV of the SFO.

As at the date of this announcement, Ms. Yao (i) did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (ii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meanings ascribed to them in the Listing Rules) of the Company.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Ms. Yao as an executive Director that need to be brought to the attention of the Shareholders.

(e) Mr. Chui

Mr. Chui Tsan Kit, aged 53, was appointed as an independent non-executive Director on 28 June 2022.

Mr. Chui obtained a degree of Master of Science in Engineering (Electronic Commerce) from the University of Hong Kong in November 2000, a degree of Master of Business Administration from the Chinese University of Hong Kong in December 2002, a degree of Master of Science in Investment Management from the Hong Kong University of Science and Technology in November 2004, a degree of Master of Laws in Chinese Business Law from the Chinese University of Hong Kong in December 2010 and a degree of Master of Corporate Governance from the Hong Kong Polytechnic University in September 2018.

In September 2011, Mr. Chui was admitted as Chartered Wealth Manager by International Academy of Financial Management. In October 2012, Mr. Chui was awarded as Certified Financial Consultant by The Institute of Financial Consultants. In November 2018, Mr. Chui was admitted as Associate of the Hong Kong Institute of Chartered Secretaries, an Associate with the designations Chartered Secretary, Chartered Governance Professional by The Chartered Governance Institute and an Associate of The Institute of Chartered Secretaries and Administrators. In March 2019, Mr. Chui was admitted as a member of CPA Australia.

Mr. Chui has worked as head of corporate advisory with CCTH CPA Limited since April 2022. He was the head of Asia Pacific and chief marketing officer of Mithera Capital (US based private equity fund) from 2018 to 2020. Mr. Chui was the chief strategic officer of Zhongtai Financial International Limited from 2014 to 2017. He was also the head of wealth management of China Galaxy International Financial Holdings Company Limited (a wholly owned subsidiary of China Galaxy Securities Co., Ltd.) from 2012 to 2014. Mr. Chui was an honorary assistant professor of the Department of Computer Science, Faculty of Engineering at The University of Hong Kong from 2006 to 2014. He was the head of warrant marketing of Bank of China (HK) Ltd. from October 2007 to February 2009. Mr. Chui was the associate director of retail operations of Sun Hung Kai Financial Limited from July 2005 to September 2007.

Mr. Chui was (i) an independent non-executive director of GR Properties Limited, a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 108) from February 2015 to February 2018; and (ii) an independent non-executive director of GET Holdings Limited (“**GET Holdings**”), a company whose shares are listed on GEM of the Stock Exchange (stock code: 8100) from April 2015 to April 2022 and the chairman of the audit committee of GET Holdings from September 2015 to November 2017.

Mr. Chui was a director of (i) Admall Capital International Limited (“**Admall**”), a private company incorporated in Hong Kong and dissolved by striking off on 4 October 2019 under the Companies Ordinance (Chapter 622 of the Law of Hong Kong); and (ii) JP Investment Holdings Limited (峻盈投資控股有限公司) (“**JP Investment**”), a private company incorporated in Hong Kong and dissolved by deregistration on 20 January 2017 under the Companies Ordinance (Chapter 622 of the Law of Hong Kong). Admall and JP Investment were inactive before dissolution. As confirmed by Mr. Chui, Admall and JP Investment were solvent prior to their dissolution.

Mr. Chui has entered into a letter of appointment with the Company as an independent non-executive Director for a term commenced on 28 June 2022 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment, Mr. Chui is entitled to an emolument of HK\$16,000 per month which was determined by the Board with reference to his duties and responsibilities with the Company, the Company’s remuneration policy and the prevailing market conditions.

As at the date of this announcement, Mr. Chui has interests in 4,000 Shares within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, Mr. Chui (i) does not hold any other position with the Company or other members of the Group; (ii) does not hold any other major appointment and professional qualification; (iii) does not have any interests in the Shares within the meaning of Part XV of the SFO; and (iv) did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

As at the date of this announcement, Mr. Chui does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meanings ascribed to them in the Listing Rules) of the Company.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Chui as an independent non-executive Director that need to be brought to the attention of the Shareholders.

(f) Ms. Lau

Ms. Lau Wai Yee, Susanna, aged 57, was appointed as an executive Director on 28 June 2022.

Ms Lau was awarded the professional diploma in Company Secretaryship and Administration by the Hong Kong Polytechnic (now known as the Hong Kong Polytechnic University) in November 1987. Ms. Lau obtained a degree of Master of Business Administration from the Hong Kong Polytechnic University in December 1999. In September 1994, Ms. Lau was admitted as Associate of the Hong Kong Institute of Company Secretaries and Associate of The Institute of Chartered Secretaries and Administrators.

Ms. Lau worked at Arthur Young & Co. (now known as Ernest & Young) with her last position of Senior I in Audit Department from July 1987 to August 1989. Ms. Lau worked at Myer Jewelry MFr. Ltd with her last position of General Manager of Sales & Marketing (China) from September 1989 to July 1994. Ms. Lau worked at Climax Paper Converters, Limited with her last position of Assistant to Chief Executive Officer from October 1996 to December 1997, and worked at Pro-Market Ltd. with her last position of Associate Director from January 1998 to 2001. Ms. Lau worked at Power Circles Dynamic Management Limited with her last position of Associate Director from December 2008 to November 2015. Ms. Lau was Director of China operations of perFACE from 2012 to 2015. Ms. Lau has worked as Chief Executive Officer of One Theory Health Tech Limited since December 2015 and has worked as the Marketing Director of Codex Genetics Limited since January 2020.

Ms. Lau was a director of Fullco Galleria Development Limited (富高建業有限公司) (“**Fullco**”), a private company incorporated in Hong Kong and dissolved by striking off on 26 March 2021 under the Companies Ordinance (Chapter 622 of the Law of Hong Kong). Fullco was inactive before dissolution. As confirmed by Ms. Lau, Fullco was solvent prior to its dissolution.

Ms. Lau has entered into a letter of appointment with the Company as an executive Director for a term commenced on 28 June 2022 to 31 December 2024, and she will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment entered into between the Company and Ms. Lau, Ms. Lau is entitled to an emolument of HK\$20,000 per month which was determined by the Board with reference to her duties and responsibilities with the Company, the Company’s remuneration policy and the prevailing market conditions.

As at the date of this announcement, Ms. Lau has interests in 8,000 Shares within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, Ms. Lau does not (i) hold any other position with the Company or other members of the Group; (ii) hold any other major appointment and professional qualification; and (iii) have any interests in the Shares within the meaning of Part XV of the SFO.

As at the date of this announcement, Ms. Lau (i) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (ii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meanings ascribed to them in the Listing Rules) of the Company.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Ms. Lau as an executive Director that need to be brought to the attention of the Shareholders.

(g) Dr. CW Wong

Dr. Wong Chun Wa, aged 49, was appointed as an executive Director on 28 June 2022. Dr. CW Wong is a director of Hong Kong Traumatology and Orthopaedics Institute, a subsidiary of the Company.

Dr. CW Wong obtained a degree of Bachelor of Medicine and Bachelor of Surgery from the Chinese University of Hong Kong in December 1998. Dr. CW Wong has become a registered medical practitioner by the Medical Council of Hong Kong since July 1999. Dr. CW Wong was admitted to the Membership of the Royal College of Surgeons of Edinburgh in May 2001 and the Fellowship of the Royal College of Surgeons of Edinburgh in the Specialty of Orthopaedic Surgery in September 2005. Dr. CW Wong was elected as a Fellow of the Hong Kong College of Orthopaedic Surgeons in July 2005. Dr. CW Wong was elected as a Fellow of the Hong Kong Academy of Medicine in the specialty of Orthopaedic Surgery in December 2005. Dr. CW Wong has been registered as a specialist in the specialty of Orthopaedics & Traumatology by the Medical Council of Hong Kong since April 2006.

Dr. CW Wong worked in the Department of Orthopaedics and Traumatology Department of Queen Elizabeth Hospital from July 1999 to June 2008, and worked in the Orthopaedics & Traumatology Department of Pamela Youde Nethersole Eastern Hospital from July 2008 to December 2008.

Dr. CW Wong has entered into a letter of appointment with the Company as an executive Director for a term commenced on 28 June 2022 to 31 December 2024, and he will be subject to rotation and re-election at general meeting of the Company in accordance with the Bye-laws. Pursuant to the letter of appointment entered into between the Company and Dr. CW Wong, Dr. CW Wong is entitled to an emolument of HK\$20,000 per month which was determined by the Board with reference to his duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

As at the date of this announcement, Dr. CW Wong has interests in 20,000 Shares within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, Dr. CW Wong does not (i) hold any other position with the Company or other members of the Group; (ii) hold any other major appointment and professional qualification; and (iii) have any interests in the Shares within the meaning of Part XV of the SFO.

As at the date of this announcement, Dr. CW Wong (i) did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (ii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meanings ascribed to them in the Listing Rules) of the Company.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Dr. CW Wong as an executive Director that need to be brought to the attention of the Shareholders.

Following the appointment of the above additional executive Directors, the number of the independent non-executive Directors falls below one-third of the Board as required under Rule 3.10(A) of the Listing Rules. The Company will identify suitable candidate to fill the vacancy within three months. Further announcement will be made by the Company when the relevant appointment is made.

The Board would like to welcome Mr. Ng, Dr. CK Wong, Dr. Law, Dr. CW Wong, Ms. Yao, Ms. Lau and Mr. Chui to join the Board.

By Order of the Board
Town Health International Medical Group Limited
Jin Zhaogen
Executive Director and Chief Executive Officer

Hong Kong, 28 June 2022

As at the date of this announcement, the executive Directors are Mr. Jin Zhaogen (Chief Executive Officer), Ms. Zhao Xiangke (Chief Financial Controller), Dr. Wong Chi Kit Nelson, Dr. Law Kwan Kin, Dr. Wong Chun Wa, Mr. Ng Ting Chi, Ms. Yao Yuan and Ms. Lau Wai Yee, Susanna; the non-executive Directors are Mr. Kong Dechang (Chairman) and Mr. Hou Jun; and the independent non-executive Directors are Mr. Ho Kwok Wah, George, MH, Mr. Yu Xuezhong, Dr. Xu Weiguo and Mr. Chui Tsan Kit.